Meta description: The Ki-67 proliferation index is an IHC-based prognostic biomarker in breast cancer. Learn what it measures, how it's scored, and its analytic limits.

---

The Ki-67 Proliferation Index in Breast Cancer: What It Measures and What It Doesn't

The Ki-67 proliferation index is among the most widely ordered and most debated biomarkers in breast pathology. It offers a numerical snapshot of how quickly a tumor is dividing, and that number feeds into prognostic thinking and, increasingly, into decisions about which classes of adjuvant therapy a patient may be eligible for. Its value is real, but so are its limitations, and understanding both is essential for anyone interpreting a pathology report that carries a Ki-67 result.

What the Test Measures

Ki-67 is a nuclear protein expressed during the active phases of the cell cycle (G1, S, G2, and mitosis) and absent in resting cells (G0). Because of this pattern, the fraction of tumor cells staining positive for Ki-67 is a proxy for the growth fraction of a tumor: the proportion of cells actively cycling at the moment of biopsy or resection. Ki-67 quantifies proliferation and nothing more. A high value does not by itself identify a particular molecular subtype, predict response to a specific drug, or substitute for hormone receptor and HER2 testing. It answers one question, how much of this tumor is dividing, and its interpretation depends heavily on the context of the other results on the report.

How It's Tested

Ki-67 is assessed by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissue, the same material used for routine histology and other IHC stains. The pathologist counts the percentage of invasive tumor cell nuclei that show positive staining, and that percentage is reported as the index.

The preanalytic and analytic sensitivities of this assay are considerable. Fixation time, antibody clone, staining protocol, and, critically, how and where the pathologist counts all influence the final number. The International Ki-67 in Breast Cancer Working Group has repeatedly emphasized that reproducibility across laboratories remains a recognized limitation, and it has issued standardized guidance on scoring methodology to narrow that variability [1], with automated image-analysis approaches since shown to improve inter-reader agreement [3]. Recommendations include specifying which regions of the tumor to score (for example, avoiding scoring only the most proliferative "hot spots" when a global average is intended), counting an adequate number of cells, and using validated protocols. Even with these measures, laboratory-to-laboratory concordance is imperfect, and this uncertainty is greatest precisely in the middle of the range, where clinical decisions are often most finely balanced [3].

What Each Result State Means

Ki-67 results are commonly reported as low, intermediate, or high, reflecting the proportion of proliferating tumor nuclei.

• A low index suggests a slowly proliferating tumor, generally associated with a more favorable prognostic profile.
• A high index indicates a rapidly proliferating tumor and is generally associated with a less favorable prognosis and greater biological aggressiveness.
• An intermediate index is the most difficult to act on. This is the zone where analytic variability has the largest practical impact: a tumor scored at the upper edge of intermediate in one laboratory might fall into the high category in another, and vice versa. The Working Group has been candid that no single universally validated cutoff cleanly separates these categories [1]; monarchE was the first phase-3 adjuvant trial to prospectively fix a standardized ≥20% threshold [2], and this is one reason intermediate values should be interpreted alongside grade, receptor status, nodal status, and other clinicopathologic features rather than in isolation.

What It Informs for Treatment Eligibility

Ki-67 is fundamentally a prognostic marker, it helps estimate the likely course of disease, and it contributes to risk stratification as one input among several. It is not, on its own, a stand-alone determinant of therapy.

In the adjuvant setting, a high Ki-67 index (≥20%) was used as an entry criterion in the monarchE trial of the CDK4/6 inhibitor abemaciclib [2][4]. That trial showed Ki-67 to be prognostic but not predictive of abemaciclib benefit, and in 2023 the FDA removed the Ki-67 ≥20% requirement from the adjuvant abemaciclib indication accordingly [2]. The historical framing was that a high Ki-67 result could help establish whether a patient fell within a composite high-risk eligibility profile (alongside nodal involvement and tumor grade), not that any individual should or should not receive a specific drug. Those decisions rest with the treating oncology team, integrating the full clinical picture.

Caveats and What's Evolving

Several caveats stand out. The absence of a single validated, universally accepted cutoff remains the central controversy [1], and clinicians should be cautious about treating any threshold as a hard biological boundary, particularly for values near a decision point, even monarchE's prospectively standardized ≥20% threshold functioned as a trial-entry convention rather than a validated biological boundary [2]. Efforts toward standardization, including calibrated scoring protocols and automated image analysis, continue to develop, and broader adoption of reproducible methods would meaningfully reduce the interlaboratory disagreement that currently undermines confidence in borderline results [3].

Ki-67 should also not be conflated with HER2-low classification, though the two often are in discussion because both are contested and both concern how finely we subdivide breast cancers. HER2-low is defined by HER2 IHC and in situ hybridization results and pertains to a distinct set of therapeutic questions; it is unrelated to the proliferation index [5][6]. Ki-67 measures cell cycling; HER2 status measures receptor expression. Confusing the two can lead to misinterpretation of a report.

Consider a practical scenario: in a node-negative, hormone receptor, positive tumor of intermediate grade, a clearly low Ki-67 and a clearly high Ki-67 pull prognostic estimates in opposite directions and may place the case on different sides of an eligibility framework. When the index instead lands in the intermediate zone, the pathologist and oncologist face the same uncertainty the assay itself carries, and the surrounding features, grade, receptor intensity, nodal status, carry proportionally more weight. In practice, the distinction to keep is straightforward: a Ki-67 value near a threshold should prompt attention to the confidence interval around that number, not a reflexive assignment to the nearest category. Ongoing methodologic work aims to make that confidence interval narrower, and its resolution would give borderline results the reliability that current practice cannot always assume.

References

1. Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021. doi:10.1093/jnci/djaa201. (IKWG consensus recommendations, T2, attributed; vault S704.)
2. Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Ki-67 subgroup analyses from monarchE. Ann Oncol. 2021. doi:10.1016/j.annonc.2021.09.015. (Central MIB-1 assay, Ki-67 ≥20% threshold, prognostic-not-predictive; FDA removed Ki-67 requirement 2023, T1; vault S414.)
3. Boyaci C, Sun W, Robertson S, et al. Independent clinical evaluation of the International Ki67 in Breast Cancer Working Group automated scoring guideline (QuPath; ICC 0.938). Biomolecules. 2021. doi:10.3390/biom11111612. (Automated Ki-67 reproducibility, T1; vault S647.)
4. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk early breast cancer (monarchE). J Clin Oncol. 2020. doi:10.1200/JCO.20.02514. (monarchE primary; Ki-67 ≥20% high-risk entry feature, T1; vault S413.)
5. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04). N Engl J Med. 2022. doi:10.1056/NEJMoa2202914. (HER2-low defined by HER2 IHC/ISH, T1; vault S320.)
6. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO, CAP Guideline Update. Arch Pathol Lab Med / J Clin Oncol. 2023. doi:10.1200/JCO.22.02864. (HER2-low is not a formal IHC reporting category, T2, attributed; vault S086.)